Myllia Biotechnology's Avatar

Myllia Biotechnology

@mylliabio.bsky.social

Primary cell CRISPR screens to accelerate drug discovery and target selection at single-cell resolution

21 Followers  |  18 Following  |  26 Posts  |  Joined: 14.01.2025  |  1.6158

Latest posts by mylliabio.bsky.social on Bluesky

Dr. Silvia Domcke’s research group at the University of Zurich combines single cell genomics and large-scale CRISPR screens to predict de novo transcription factor activity in mammalian cells and engineer cell state transitions. Previously, Silvia led a computational team at a San Francisco biotech startup, applying in vivo Perturb-Seq for target discovery in complex diseases. A biochemist by training, she became enamored with comparative genomics and perturbation approaches at Memorial Sloan-Kettering Cancer Center in New York, built a foundation in gene regulatory mechanisms during her PhD at the Friedrich Miescher Institute in Basel and expanded this expertise to high-throughput single cell methods during her postdoc at the University of Washington in Seattle.

Dr. Silvia Domcke’s research group at the University of Zurich combines single cell genomics and large-scale CRISPR screens to predict de novo transcription factor activity in mammalian cells and engineer cell state transitions. Previously, Silvia led a computational team at a San Francisco biotech startup, applying in vivo Perturb-Seq for target discovery in complex diseases. A biochemist by training, she became enamored with comparative genomics and perturbation approaches at Memorial Sloan-Kettering Cancer Center in New York, built a foundation in gene regulatory mechanisms during her PhD at the Friedrich Miescher Institute in Basel and expanded this expertise to high-throughput single cell methods during her postdoc at the University of Washington in Seattle.

Don’t forget to register and submit an abstract for the 'High-Content CRISPR Screening' conference, which will take place in Vienna, Austria, on 18–19 March 2026!

Conference website: www.perturb2026.bio

Meet the Speaker: Silvia Domcke

14.10.2025 10:58 — 👍 1    🔁 0    💬 0    📌 1
Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.

Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.

Are you interested in single-cell genomics, multi-modal perturbation data and drug target discovery? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria!

Meet the Speaker: Radu Rapiteanu

www.perturb2026.bio

02.10.2025 08:24 — 👍 3    🔁 1    💬 0    📌 0
Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.

Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
perturb2026.bio

Meet the Speaker: Mathew Garnett

@mgarnett.bsky.social

29.09.2025 12:32 — 👍 3    🔁 1    💬 0    📌 0
Prior to co-founding Relation Therapeutics, Dr. Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access.

Prior to co-founding Relation Therapeutics, Dr. Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access.

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the website:
perturb2026.bio

Meet the Speaker: Jake P. Taylor-King

23.09.2025 10:52 — 👍 2    🔁 0    💬 0    📌 0
Myllia Biotechnology is looking forward to explore new collaborations in early-stage drug target discovery and CRISPR-based functional genomics: Meet Henrik Schmidt at 📍 BioJapan 2025 in Yokohama, Tokyo from October 8-10 to discuss your next drug discovery partnerships! At Myllia, we perform high-content CRISPR screens in primary human cells, incl. epithelial cells, T cells, dendritic cells and macrophages. Our technology platform enables the systematic identification of genetically validated, high-value targets in autoimmune disease, inflammation and oncology. 📰 Visit www.myllia.com for more information 📩 Contact us via email: info@myllia.com

Myllia Biotechnology is looking forward to explore new collaborations in early-stage drug target discovery and CRISPR-based functional genomics: Meet Henrik Schmidt at 📍 BioJapan 2025 in Yokohama, Tokyo from October 8-10 to discuss your next drug discovery partnerships! At Myllia, we perform high-content CRISPR screens in primary human cells, incl. epithelial cells, T cells, dendritic cells and macrophages. Our technology platform enables the systematic identification of genetically validated, high-value targets in autoimmune disease, inflammation and oncology. 📰 Visit www.myllia.com for more information 📩 Contact us via email: info@myllia.com

Post image

Meet Myllia's @henrik-hs.bsky.social at #BioJapan2025 in Yokohama, Tokyo from October 8-10 to discuss your next CRISPR-based drug target discovery partnerships!

Websites:
myllia.com
myllia.com/events/bio-j...

Contact us via email: info@myllia.com

22.09.2025 11:22 — 👍 3    🔁 1    💬 0    📌 0
Abstract submissions are now open for the conference on "High-Content CRISPR Screening", taking place in Vienna this March 2026. We invite researchers from across the globe to share their latest work and join the discussion shaping the future of CRISPR screening and genome editing. Scientific themes include * CRISPR-based screening strategies * Perturb-seq and CROP-seq methods * Computational analysis and data interpretation * AI models of human cells * Imaging-based CRISPR screens Date: March 18 & 19, 2026 Location: Vienna, Austria

Abstract submissions are now open for the conference on "High-Content CRISPR Screening", taking place in Vienna this March 2026. We invite researchers from across the globe to share their latest work and join the discussion shaping the future of CRISPR screening and genome editing. Scientific themes include * CRISPR-based screening strategies * Perturb-seq and CROP-seq methods * Computational analysis and data interpretation * AI models of human cells * Imaging-based CRISPR screens Date: March 18 & 19, 2026 Location: Vienna, Austria

High-Content CRISPR Screening Conference

March 18-19, 2026 | Vienna, Austria

Abstract submission is now open! Don’t miss the chance to hear from an outstanding line-up of speakers and connect with leading researchers in the field.

Register now: perturb2026.bio

19.09.2025 09:10 — 👍 2    🔁 0    💬 0    📌 0
Dr. Wei Li is currently an associate professor at the University of Maryland School of Medicine (UMSOM) and the University of Maryland-Institute for Health Computing (UM-IHC). His laboratory uses novel computational, AI/ML and genome engineering approaches to understand the functions of the mammalian genome, especially in the context of human physiology and disease. His laboratory developed several widely used algorithms for genome editing, RNA sequencing, functional genomics screening, and Perturb-seq/CROP-seq. Collaborating with many scientists around the world, his laboratory developed models to design new gene editing systems with high efficiency and specificity, applied novel AI/ML approaches in various types of biological and biomedical data, and identified clinically relevant hits and synergistic targets in critical human diseases including breast/prostate cancer, brain tumor and infectious diseases.

Dr. Wei Li is currently an associate professor at the University of Maryland School of Medicine (UMSOM) and the University of Maryland-Institute for Health Computing (UM-IHC). His laboratory uses novel computational, AI/ML and genome engineering approaches to understand the functions of the mammalian genome, especially in the context of human physiology and disease. His laboratory developed several widely used algorithms for genome editing, RNA sequencing, functional genomics screening, and Perturb-seq/CROP-seq. Collaborating with many scientists around the world, his laboratory developed models to design new gene editing systems with high efficiency and specificity, applied novel AI/ML approaches in various types of biological and biomedical data, and identified clinically relevant hits and synergistic targets in critical human diseases including breast/prostate cancer, brain tumor and infectious diseases.

The registration and abstract submission is now open for the "High-Content CRISPR Screening" conference on March 18–19, 2026, in Vienna, Austria!

Conference website:
www.perturb2026.bio

Abstract submission:
www.perturb2026.bio/abstract-sub...

Meet the Speaker: Wei Li

19.09.2025 07:28 — 👍 4    🔁 0    💬 0    📌 0
Dr. Francesco Iorio is a Research Group Leader at Human Technopole in Milan, where he leads a Computational Pharmacogenomics and Functional Genomics Laboratory. His research focuses on characterising cancer vulnerabilities and synthetic lethalities through large-scale CRISPR screening and exploiting them for early anti-cancer drug discovery. He is the recipient of a European Research Council (ERC) Consolidator Grant focused on developing predictive tools for personalised oncology. Francesco has contributed to foundational tools and resources for CRISPR-data processing, interpretation and use for therapeutic target prioritisation, and has led efforts to develop computational methods for drug repurposing and precision oncology. Prior to joining Human Technopole, he worked at the Wellcome Sanger Institute and EMBL-EBI in Cambridge, UK. He is passionate about the intersection of artificial intelligence and biomedical research and about building collaborative, interdisciplinary communities in functional genomics.

Dr. Francesco Iorio is a Research Group Leader at Human Technopole in Milan, where he leads a Computational Pharmacogenomics and Functional Genomics Laboratory. His research focuses on characterising cancer vulnerabilities and synthetic lethalities through large-scale CRISPR screening and exploiting them for early anti-cancer drug discovery. He is the recipient of a European Research Council (ERC) Consolidator Grant focused on developing predictive tools for personalised oncology. Francesco has contributed to foundational tools and resources for CRISPR-data processing, interpretation and use for therapeutic target prioritisation, and has led efforts to develop computational methods for drug repurposing and precision oncology. Prior to joining Human Technopole, he worked at the Wellcome Sanger Institute and EMBL-EBI in Cambridge, UK. He is passionate about the intersection of artificial intelligence and biomedical research and about building collaborative, interdisciplinary communities in functional genomics.

The registration and abstract submission for the "High-Content CRISPR Screening" conference on March 18–19, 2026, in Vienna, Austria is now open!

Conference website: lnkd.in/d8KACZy5
Abstract submission: lnkd.in/dcyuwXNM

Meet the Speaker: Francesco Iorio

@francescoiorio.bsky.social

18.09.2025 12:11 — 👍 1    🔁 0    💬 0    📌 0
Dr. Luke Gilbert is a Professor at the University of California, San Francisco and a Core Investigator at the Arc Institute. Dr. Gilbert was an early pioneer in repurposed CRISPR systems that are used to turn genes on (CRISPRa) and off (CRISPRi). More recently, the Gilbert lab has developed new strategies for editing heritable epigenetic memories (CRISPRoff/on) and for systematically mapping human genetic interactions at very large scales or at single cell resolution. Medically, the Gilbert lab is focusing on using CRISPR functional genomics expertise to tackle big problems in cancer biology.

Dr. Luke Gilbert is a Professor at the University of California, San Francisco and a Core Investigator at the Arc Institute. Dr. Gilbert was an early pioneer in repurposed CRISPR systems that are used to turn genes on (CRISPRa) and off (CRISPRi). More recently, the Gilbert lab has developed new strategies for editing heritable epigenetic memories (CRISPRoff/on) and for systematically mapping human genetic interactions at very large scales or at single cell resolution. Medically, the Gilbert lab is focusing on using CRISPR functional genomics expertise to tackle big problems in cancer biology.

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
lnkd.in/d8KACZy5

Meet the Speaker: Luke Gilbert

12.09.2025 09:28 — 👍 2    🔁 2    💬 0    📌 0
Dr. Christoph Bock is a Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Professor of Medical Informatics at the Medical University of Vienna. His research combines experimental biology (single-cell sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine (https://www.bocklab.org & https://bsky.app/profile/bocklab.bsky.social).

Dr. Christoph Bock is a Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Professor of Medical Informatics at the Medical University of Vienna. His research combines experimental biology (single-cell sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine (https://www.bocklab.org & https://bsky.app/profile/bocklab.bsky.social).

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
lnkd.in/d8KACZy5

Meet the Speaker: Christoph Bock

@bocklab.bsky.social

09.09.2025 14:11 — 👍 6    🔁 3    💬 0    📌 0
Meet Myllia at: 📍 BIO Japan 2025 - Tokyo, 8-10 October 📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October 📍 BIO Europe 2025 - Vienna, 3-5 November

Meet Myllia at: 📍 BIO Japan 2025 - Tokyo, 8-10 October 📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October 📍 BIO Europe 2025 - Vienna, 3-5 November

Exciting times ahead for @mylliabio.bsky.social in Q4 2025

📍 BIO Japan 2025 - Tokyo, 8-10 October
📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October
📍 BIO Europe 2025 - Vienna, 3-5 November

📰 Website: www.myllia.com
📩 Contact: info@myllia.com

08.09.2025 08:23 — 👍 2    🔁 1    💬 0    📌 0
At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes.

At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes.

We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models:   - 150+ CRISPR screens in cell lines and primary human cells - 35+ collaborative projects worldwide - End-to-end workflows from experimental screening to computational analysis

We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models:   - 150+ CRISPR screens in cell lines and primary human cells - 35+ collaborative projects worldwide - End-to-end workflows from experimental screening to computational analysis

Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays. 👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com

Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays. 👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com

🧬 Meet #TeamMyllia

Our mission is to accelerate drug discovery through high-content CRISPR screening:

- 150+ CRISPR screens in cell lines and primary cells
- 35+ collaborative projects worldwide
- End-to-end workflows from screening to bioinformatics

www.myllia.com

21.08.2025 11:20 — 👍 4    🔁 2    💬 0    📌 0
Post image

📢 @mylliabio.bsky.social is heading to #IUIS2025 - we’re excited to share that Anke Loregger, Myllia’s Director of R&D, will attend the International Congress of Immunology (IUIS) 2025 in Vienna! Interested in the VISTA platform?

Poster: II.265 on Wednesday, August 20 at 12.15 PM

www.myllia.com

11.08.2025 13:22 — 👍 3    🔁 2    💬 0    📌 0
Post image

🗓️ @mylliabio.bsky.social sponsors the first conference on "High-Content CRISPR Screening" from March 18-19, 2026 in Vienna: perturb2026.bio

Scientific topics:
🔬 CRISPR-based screening strategies
🧬 Perturb-Seq & CROP-Seq
💻 Computational analyses
💻 AI models of human cells
📸 Image-based screens

07.08.2025 11:46 — 👍 5    🔁 6    💬 0    📌 0
Post image

🧬 Unlocking target discovery in primary human dendritic cells with VISTA™

At @mylliabio.bsky.social, we’re enabling functional genomics in primary immune cells. Our VISTA™ platform combines pooled CRISPRi with scRNA-Seq to systematically map gene function at scale!

Contact us via: info@myllia.com

05.08.2025 14:01 — 👍 3    🔁 2    💬 0    📌 0
Post image Post image Post image

🔬 Wrapping up an exciting week at #FOCIS2025 in Boston!

We were thrilled to have Sumit Pawar, Associate Director of R&D at @mylliabio.bsky.social, present our latest research on the VISTA™ platform!

📩 Interested in partnering with Myllia? Reach out to us at info@myllia.com

27.06.2025 09:42 — 👍 0    🔁 0    💬 0    📌 0
Post image

🧬 Join @mylliabio.bsky.social at #FOCIS2025 in Boston!

We’re excited to share that our colleague Sumit Pawar will be presenting our latest work on the VISTA™ platform at #FOCIS25

📍 Poster: Th146
📅 Date: Thursday, June 26, 2025

myllia.com

24.06.2025 14:18 — 👍 2    🔁 0    💬 0    📌 0
Post image

Vienna, June 2025 - @mylliabio.bsky.social, a leader in functional genomics in primary human cells, has launched VISTA™ - the first platform enabling CRISPR screens in primary human macrophages and dendritic cells!

www.myllia.com

Press Release: www.biospace.com/press-releas...

10.06.2025 08:20 — 👍 3    🔁 1    💬 0    📌 0
Post image

Compressed CROP-Seq screens enable functional genomics at scale: At @mylliabio.bsky.social, we are pushing the limits of #CRISPR screening with compressed genome-wide screens — a powerful method for dissecting cellular states and boosting screening capacity without compromising resolution!

20.05.2025 15:00 — 👍 3    🔁 1    💬 0    📌 0
Post image

It's about one month to go until BIO US 2025 in Boston!

Are you attending as well? If so, please reach out to our CSO Tilmann Buerckstuemmer and our BD Manager Henrik Schmidt who will be attending #BIO2025 from June 16-19, 2025.

Contact us via:
📩 info@myllia.com
📰 www.myllia.com

13.05.2025 12:24 — 👍 0    🔁 0    💬 0    📌 0
Post image

Looking forward to representing @mylliabio.bsky.social at the #SwissBiotechDay 2025 in Basel and discussing drug target ID/validation powered by single-cell CRISPR screens in primary human cells!

🎯 Explore Myllia's platform: myllia.com
📩 Contact: info@myllia.com

#TeamMyllia #CRISPR #scRNASeq

15.04.2025 15:04 — 👍 1    🔁 2    💬 0    📌 0
Post image

We will be at #AACR25 in Chicago, USA

Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages"

🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST
🎯 Poster: LB043, Section 52

myllia.com
#CRISPR #scRNASeq #TargetDiscovery #FGX

08.04.2025 14:14 — 👍 4    🔁 1    💬 0    📌 0
Post image

🚀 At @mylliabio.bsky.social, we're advancing scRNA-Seq in primary human cells with our targeted sequencing (TA-Seq) platform!

Key insights:
• TA-Seq uses 10K reads/cell vs. 50K reads/cell for WTA
• Low-abundance mRNAs are detected more effectively w/ TA-Seq & multiplexed primer panels

myllia.com

05.03.2025 10:46 — 👍 2    🔁 1    💬 0    📌 0
Preview
Decoding heterogeneous single-cell perturbation responses - Nature Cell Biology In two independent studies, Song et al. and Jiang, Dalgarno et al. present computational frameworks, perturbation-response score and Mixscale, respectively, to determine individual cellular variation ...

A team at @mylliabio.bsky.social contributed one of the largest single-cell #CRISPR #perturbation #screens published today: nature.com/articles/s41...

The lab of Wei Li developed the perturbation-response score (PS) allowing the quantification of diverse perturbation responses in single cells!

26.02.2025 12:24 — 👍 3    🔁 1    💬 0    📌 0
Post image

🧬 At @mylliabio.bsky.social, we're pushing the boundaries of #scCRISPR screens in primary human T cells. For example, we focus on scalable #CROPSeq screens to uncover key mediators of T helper cell differentiation, particularly Th2 cells!

Reach out via: myllia.com/contact/
#CRISPR #scRNASeq #TCells

14.02.2025 11:56 — 👍 1    🔁 1    💬 0    📌 0
Post image

📢 One month to go! @mylliabio.bsky.social will be at #BIOEuropeSpring 2025 in Milan, Italy! Would you like to get in touch? Meet our BD Manager @henrik-hs.bsky.social on site to explore #CRISPR-based #functional #genomics screens in primary human cells!

Learn more about CROP-Seq here: myllia.com

11.02.2025 15:19 — 👍 5    🔁 2    💬 0    📌 0
Post image

Can #AI predict #CRISPR perturbation outcomes?

@mylliabio.bsky.social's CROP-Seq dataset provides a critical resource for AI-driven #Foundation #Models of the Human Cell: myllia.com/resources/cr...

We're the global leader in CRISPR-based functional genomics screens - contact us via info@myllia.com

03.02.2025 15:36 — 👍 5    🔁 2    💬 0    📌 0
Post image

🔬 At @mylliabio.bsky.social, we're revolutionizing target discovery with CROP-Seq in primary human T cells:

- Custom assay development
- SLICE protocol for functional screening
- Integration of CITE-Seq & scRNA-Seq

Ready to elevate your research? Contact us at info@myllia.com and visit: myllia.com

23.01.2025 11:15 — 👍 1    🔁 1    💬 0    📌 0

@mylliabio is following 18 prominent accounts